If you have been reading about IRAP and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-05-06. Numbers and descriptions here follow the published literature rather than marketing material.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Structural features include amino acid residues and a hexanoic acid group. |
| Common synonyms | PNB-0408; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Names vary by source and should be verified. |
| Origin | Angiotensin IV research | Developed as a modified analog in academic laboratories. |
| Primary research focus | Synaptic growth and cognition | Studied mainly in cultured neurons and rodent models. |
| Regulatory status | Not approved as a drug | No accepted human therapeutic or supplement status. |
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
== Other considerations == According to the U.S. Medical Eligibility Criteria for Contraceptive Use, published by the CDC, women and adolescents under the age of 20 and women who have not given birth are classified in category 2 for IUD use, mainly due to "the risk for expulsion from nulliparity and STIs from sexual behavior in younger age groups." According to the CDC, benefits generally outweigh the risks, and IUDs are recommended for young and nulliparous women, although more careful attention may be required. Women over age 20 and those who have previously given birth are placed in category 1, meaning no special concerns are placed on use. Modern IUDs do not lead to infertility or make it harder for a woman to become pregnant, and fertility typically returns within days of removal. Some prior studies found an association between infertility and the Dalkon Shield, an early IUD design which is no longer available. Modern IUDs do not increase infection. The earlier Dalkon Shield may have been problematic because it contained multifilament strings, which provided bacteria a space to grow and move up the string. IUDs manufactured after 2008 use monofilament strings to prevent this from happening. However, as with any medical procedure, IUDs can lead to increased risk of infection immediately after the insertion. Menstrual cup companies recommend that women with IUDs who are considering using menstrual cups should consult with their gynecologists before use.
=== 20th century === During the 1970s and 80s, when the first thorough fundamental studies with nanoparticles were underway in the United States by Granqvist and Buhrman and Japan within an ERATO Project, researchers used the term ultrafine particles. However, during the 1990s, when the National Nanotechnology Initiative was launched in the United States, the term nanoparticle became more common, for example, see the same senior author's paper 20 years later addressing the same issue, lognormal distribution of sizes.
== Society and culture == Some cultures regard the liver as the seat of the soul. In Greek mythology, the gods punished Prometheus for revealing fire to humans by chaining him to a rock where a vulture (or an eagle) would peck out his liver, which would regenerate overnight (the liver is the only human internal organ that actually can regenerate itself to a significant extent). Many ancient peoples of the Near East and Mediterranean areas practiced a type of divination called haruspicy or hepatomancy, where they tried to obtain information by examining the livers of sheep and other animals. In Plato, and in later physiology, the liver was thought to be the seat of the darkest emotions (specifically wrath, jealousy and greed) which drive men to action. The Talmud (tractate Berakhot 61b) refers to the liver as the seat of anger, with the gallbladder counteracting this. The Persian, Urdu, and Hindi languages (جگر or जिगर or jigar) refer to the liver in figurative speech to indicate courage and strong feelings, or "their best"; e.g., "This Mecca has thrown to you the pieces of its liver!". The term jan e jigar, literally "the strength (power) of my liver", is a term of endearment in Urdu. In Persian slang, jigar is used as an adjective for any object which is desirable, especially women. In the Zulu language, the word for liver (isibindi) is the same as the word for courage. In English the term 'lily-livered' is used to indicate cowardice from the medieval belief that the liver was the seat of courage. Spanish hígados also means "courage".
molar concentration Also molarity, amount concentration, or substance concentration. A measure of the concentration of a chemical species, especially of a solute in a solution, in terms of the amount of the species per unit volume of solution. Molarity is typically expressed in units of moles per litre (mol/L); a solution with a concentration of exactly 1 mol/L is commonly said to be 1 molar, abbreviated 1 M. Contrast molality.
Sources: en.wikipedia.org
In February 2015, Labcorp acquired Covance for $6.1 billion. In October 2015, Labcorp acquired Safe Foods International Holdings and its two operating companies, International Food Network and The National Food Laboratory, expanding its capabilities in food and beverage product-development and product-integrity. In March 2016, Labcorp acquired Pathology Inc., a provider of reproductive donor testing as well as anatomic, molecular and digital pathology services focused on women's health. In September 2016, Labcorp acquired Sequenom for $371 million including debt, expanding its operations in Europe and Asia. In October 2016, Labcorp acquired ClearPath Diagnostics, a provider of laboratory diagnostic services in the Northeastern United States, from Shore Capital Partners. In May 2017, Labcorp acquired Pathology Associates Medical Laboratories from Providence Health & Services and Catholic Health Initiatives. In September 2017, Labcorp acquired Chiltern, a contract research organization (CRO), for $1.2 billion, and contributed it to Covance. In 2019, Labcorp acquired Wellness Corporate Solutions, a workplace wellness company.
== Atom economy == The advantage in atom economy of using NCAs for peptide formation is that there is no need for a protecting group on the functional group reacted with the amino acid. For example, the Merrifield synthesis depends on the use of Boc and Bzl protecting groups, which need be removed after the reaction. In the case of Bailey peptide synthesis, the free peptide is directly obtained after the reaction. However, unwanted and difficult to remove by-products may be formed. An N-substitution of the NCA (for example, by an o-nitrophenylsulfenyl group) can simplify the subsequent purification process, but on the other hand deteriorates the atom economy of the reaction. The synthesis of NCAs can be carried out by the Leuchs reaction or by the reaction of N-(benzyloxycarbonyl)-amino acids with oxalyl chloride. In the latter case, again the procedure is less efficient in the sense of atom economy.
=== Recreational use === A herbal remedy called Krypton was found to contain kratom leaf powder and desmetramadol. Krypton was reportedly linked to at least 9 accidental opioid overdose deaths in Sweden during 2010–2011.
=== South Korea === The crisis has not had a dramatic impact on the lives of most South Koreans, and energy minister Kim Sung-hwan has said that the country would not experience problems with supply for over a year. However, the Korean Government launched an energy-saving campaign, encouraging its citizens to have brief showers, and limit their use of washing machines, and it has postponed the decommissioning of coal-fired power plants as well as reducing the limit on electricity made from coal.
=== Newsweek's America's Best High Schools === In June 2010, seven PGCPS high school were listed in Newsweek's annual list of the top 1600 high schools in the nation. This was up from five county high schools which made the list from the previous year. The 2010 list included Eleanor Roosevelt High School in Greenbelt (#409), Oxon Hill High School in Oxon Hill (#957), Bowie High School in Bowie (#1,173), Laurel High School in Laurel (#1,343), High Point High School in Beltsville (#1,361), Central High School in Capitol Heights (#1,429), and Parkdale High School in Riverdale (#1,481). The schools are ranked on the number of Advanced Placement, International Baccalaureate and/or Cambridge tests taken by all students in a school in 2009, divided by the number of graduating seniors, called the "Challenge Index". The schools represent the top six percent of all public high schools in America. In June 2009, five PGCPS high schools were named in the best high schools list. It included Bowie High School in Bowie, Charles Herbert Flowers High School in Springdale, High Point High School in Beltsville, Oxon Hill High School in Oxon Hill, and Eleanor Roosevelt High School in Greenbelt. Eleanor Roosevelt ranked the highest out of county schools at 372nd on the nationwide list, Oxon Hill ranked 918th, High Point ranked 961st, Bowie ranked 1,370th, and Charles Herbert Flowers ranked 1,445th.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide-like compound studied primarily in preclinical models. It is often classified as an angiotensin IV analog and has been investigated for effects on neuronal connectivity. It is not an approved drug or dietary supplement.
The exact mechanism is uncertain. Some research proposes activation of hepatocyte growth factor/c-Met signaling, while other evidence implicates insulin-regulated aminopeptidase. Multiple pathways may contribute, depending on the experimental system.
Published large-scale human trials are lacking. Most available data come from cell cultures and animal studies. As a result, human safety, appropriate dosing, and clinical effectiveness are not established.
Dihexa is a synthetic peptide derived from angiotensin IV and studied for effects on synaptic plasticity. It is often described as a hepatocyte growth factor mimetic. It is not an approved medication.